Tvardi Therapeutics Reports Positive Interim Phase 2 HCC Data and Encouraging IPF Post-Hoc Analysis

summarizeResumen

The updated corporate presentation highlights significant progress in Tvardi's clinical pipeline. The interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma (HCC) shows a high disease control rate (92%) and objective response rate (33%), which compares favorably to existing therapies and suggests strong potential in an area of high unmet need. While the initial TTI-101 idiopathic pulmonary fibrosis (IPF) trial faced challenges, the detailed post-hoc analysis revealed positive trends in fibrosis reduction, IL-6 decline, and FVC improvement, indicating a potential therapeutic effect. These clinical advancements, particularly the promising HCC data, are crucial for a micro-cap biotech and could significantly impact the company's valuation and future development strategy. Investors should monitor the upcoming topline results for the Phase 2 HCC trial in 1H 2026.

check_boxEventos clave

• Positive Interim HCC Data

  The TTI-101 Phase 1b/2 trial in hepatocellular carcinoma (HCC) demonstrated a 92% disease control rate and 33% objective response rate, which compares favorably to third-party trials.

• Encouraging IPF Post-Hoc Analysis

  A post-hoc analysis of the TTI-101 idiopathic pulmonary fibrosis (IPF) trial indicated greater declines in fibrosis score and IL-6 levels, and an increase in FVC among treated patients, despite initial trial challenges.

• TTI-109 Prodrug Advancement

  The company is progressing TTI-109, a prodrug designed to enhance TTI-101 delivery, with Phase 1 healthy volunteer data anticipated in the first half of 2026.

• Cash Runway Update

  Tvardi Therapeutics reported $36.5 million in cash and equivalents as of September 30, 2025, providing an anticipated cash runway into Q4 2026.

auto_awesomeAnalisis

The updated corporate presentation highlights significant progress in Tvardi's clinical pipeline. The interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma (HCC) shows a high disease control rate (92%) and objective response rate (33%), which compares favorably to existing therapies and suggests strong potential in an area of high unmet need. While the initial TTI-101 idiopathic pulmonary fibrosis (IPF) trial faced challenges, the detailed post-hoc analysis revealed positive trends in fibrosis reduction, IL-6 decline, and FVC improvement, indicating a potential therapeutic effect. These clinical advancements, particularly the promising HCC data, are crucial for a micro-cap biotech and could significantly impact the company's valuation and future development strategy. Investors should monitor the upcoming topline results for the Phase 2 HCC trial in 1H 2026.